Lunai Bioworks (NASDAQ:LNAI) Issues Quarterly Earnings Results

Lunai Bioworks (NASDAQ:LNAI) posted its earnings results on Friday. The company reported ($0.10) earnings per share for the quarter, FiscalAI reports. The company had revenue of $0.02 million during the quarter.

Lunai Bioworks Stock Down 7.0%

LNAI opened at $0.26 on Friday. The firm has a market cap of $6.22 million, a price-to-earnings ratio of 5.14 and a beta of 0.34. Lunai Bioworks has a 52 week low of $0.15 and a 52 week high of $4.50. The business’s 50 day moving average is $0.34 and its two-hundred day moving average is $0.72.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on LNAI shares. Wall Street Zen cut Lunai Bioworks from a “hold” rating to a “sell” rating in a research note on Saturday, February 21st. Weiss Ratings restated a “sell (e+)” rating on shares of Lunai Bioworks in a research note on Friday, April 10th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Lunai Bioworks stock. Millennium Management LLC purchased a new position in shares of Lunai Bioworks Inc. (NASDAQ:LNAI) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned 0.87% of Lunai Bioworks as of its most recent SEC filing. Hedge funds and other institutional investors own 71.41% of the company’s stock.

About Lunai Bioworks

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.